![Mark Bradley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Bradley
Oprichter bij Edinburgh Molecular Imaging Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
David Jeans | M | 74 |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | 9 jaar |
Alison Jane Williamson | F | - |
BioCaptiva Ltd.
![]() BioCaptiva Ltd. BiotechnologyHealth Technology BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler. | 2 jaar |
Jeremy Wheeler | M | 58 |
BioCaptiva Ltd.
![]() BioCaptiva Ltd. BiotechnologyHealth Technology BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler. | - |
Frank Armstrong | M | 67 |
BioCaptiva Ltd.
![]() BioCaptiva Ltd. BiotechnologyHealth Technology BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler. | 3 jaar |
Bernhard Sixt | M | - |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | 6 jaar |
Andrew Dunlop | M | 52 |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | - |
Elizabeth Ann Roper | M | 50 |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | - |
Chris Haslett | M | - |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | 10 jaar |
Kev Dhaliwal | M | - |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | 10 jaar |
Timothy John Aitman | M | 66 |
BioCaptiva Ltd.
![]() BioCaptiva Ltd. BiotechnologyHealth Technology BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler. | - |
Stephen Little | M | 67 |
BioCaptiva Ltd.
![]() BioCaptiva Ltd. BiotechnologyHealth Technology BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Ian Wilson | M | - |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | 4 jaar |
Gordon Davis | M | 67 |
Edinburgh Molecular Imaging Ltd.
![]() Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 13 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Mark Bradley
- Persoonlijk netwerk